Beijing, Beijing, China The fund was located in Asia if to be more exact in China. The leading representative office of defined VC is situated in the Beijing.
For fund there is no match between the location of its establishment and the land of its numerous investments - United States. The fund has no exact preference in a number of founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Among the most successful fund investment fields, there are Analytics, Health Diagnostics. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Vividion Therapeutics, Gritstone Oncology, Quanterix.
The top activity for fund was in 2019. The fund is constantly included in less than 2 deals per year. The common things for fund are deals in the range of 50 - 100 millions dollars. Speaking about the real fund results, this VC is 5 percentage points more often commits exit comparing to other organizations. Opposing the other organizations, this Trinitas Capital works on 21 percentage points more the average amount of lead investments. The increased amount of exits for fund were in 2018.
The standard case for the fund is to invest in rounds with 9 partakers. Despite the Trinitas Capital, startups are often financed by The Column Group, Versant Ventures, In-Q-Tel. The meaningful sponsors for the fund in investment in the same round are Versant Ventures, The Column Group, ARCH Venture Partners. In the next rounds fund is usually obtained by Topspin Partners, The Column Group, Taiho Ventures.
Related Funds
| Fund Name | Location |
| AXA Life Japan | Chiyoda, Japan |
| Brighton Health Group | California, Spring Valley, United States |
| Forte Capital | New York, Rochester, United States |
| Galaxy Capital Partners | California, San Francisco, United States |
| Guochuang Kaiyuan fund | - |
| Inktomi Corporation | California, Foster City, United States |
| Lens Technology | China, Fujian, Hunan |
| Maintrend Capital | Beijing, Beijing, China |
| RC Ventures | Bangladesh, Dhaka, Dhaka |
| Reliance Mutual Fund | India, Maharashtra, Mumbai |
| Riverstone Holdings | New York, New York, United States |
| Sofiouest | France, Ile-de-France, Paris |
| Soul Capital Limited | China, Hong Kong, Hong Kong Island |
| SourceN | Bangalore, India, Karnataka |
| SPCC | Japan, Tokyo |
| Supcon Group | China, Hangzhou, Zhejiang |
| Taiyizhishang | China, Hangzhou, Zhejiang |
| Velocity Capital Management | California, Palo Alto, United States |
| Yochy Investments | Israel, Tel Aviv, Tel Aviv District |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
HiberCell | $67M | 19 May 2021 | New York, New York, United States | ||
Vividion Therapeutics | $82M | 30 Apr 2019 | San Diego, California, United States | ||
ORIC Pharmaceuticals | $50M | 21 Feb 2018 | South San Francisco, California, United States | ||
Gritstone Oncology | $93M | 07 Sep 2017 | California, United States |
– HiberCell, a NYC-based biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, completed a Series B financing round for gross proceeds of $67.4m.
– The company closed on a $30m debt facility with Hercules Capital, Inc. (NYSE: HTGC).
– The Series B round included new investors Huizenga Capital Management, Monashee Investment Management, funds managed by Tekla Capital Management LLC, Hercules Capital, Mount Sinai Innovation Partners and other undisclosed investors.
– Returning investors, including ARCH Venture Partners, Magnetic Ventures, Bristol Myers Squibb, Trinitas Capital, and others from the Series A syndicate also participated in the round.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
HiberCell | $67M | 19 May 2021 | New York, New York, United States | ||
Vividion Therapeutics | $82M | 30 Apr 2019 | San Diego, California, United States | ||
ORIC Pharmaceuticals | $50M | 21 Feb 2018 | South San Francisco, California, United States | ||
Gritstone Oncology | $93M | 07 Sep 2017 | California, United States |
